Novel Intervention Strategies for Helicobacter pylori Treatment

Author(s): Brian Noonan, Richard A. Alm

Journal Name: Current Drug Targets - Infectious Disorders
Continued as Infectious Disorders - Drug Targets

Volume 2 , Issue 4 , 2002


Helicobacter pylori infects the gastric mucosa of almost half of the worlds population and infection is associated with several gastrointestinal diseases, ranging in severity from superficial and chronic gastritis to duodenal ulceration and gastric adenocarcinoma. Developing new therapeutics against a bacterium with such a unique niche has proven challenging, and the current therapy is complex and increase of bacterial resistance to current antimicrobials and treatment failure has identified a need for newer, more potent compounds. Access to the genomic sequence of several H. pylori isolates has allowed a more focused, target - specific approach to the development of new therapeutics.

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2002
Page: [331 - 338]
Pages: 8
DOI: 10.2174/1568005023342209
Price: $58

Article Metrics

PDF: 1